Banner

Ribosome and mRNA Display

Ribosome and mRNA Display

  • Background
  • Platform Overview

Ribosome and mRNA display have unique advantages in antibody discovery and screening. Leveraging our team's extensive expertise, we have successfully established an innovative ribosome and mRNA display platform. This cutting-edge platform offers a unique solution for the efficient screening of single domain antibodies.

Introduction to Ribosome and mRNA Display

Ribosome and mRNA display is a completely cell-free system for the in vitro selection of proteins and peptides from large libraries. The method combines in vitro translation, selection, and amplification steps to create a powerful tool for protein evolution. It leverages the natural process of protein synthesis by keeping the protein progenitor attached to the ribosome-mRNA complex, allowing the selection of proteins based on their binding properties.

Ribosome display selection cycle.Fig. 1 The process of ribosome and mRNA display. (Galán A, et al., 2016)

Our Services

Our company has invested in the development of state-of-the-art ribosome and mRNA display platforms that are able to provide comprehensive services for single domain antibodies (sdAbs) screening. Our meticulous antibody screening process guarantees the production of sdAbs with exceptional affinity and specificity. This enables us to provide you with a valuable and reliable resource for your research, diagnostics, and therapeutic development needs.

Workflow of Ribosome and mRNA Display

sdAb Library Construction

The constructed sdAb library consists of a vast repertoire of antibody variable domains, which can be derived from natural or synthetic sources. The library is designed to maximize diversity and ensure comprehensive coverage of the sequence space.

Selection and Binding

The ribosome-mRNA-protein complexes are exposed to the target of interest and subjected to selection using affinity chromatography columns, immobilized surfaces, or magnetic beads coated with the target molecule. Complexes that bind well to the target are immobilized.

Iterative Selection and Evolution

The cDNA is amplified using PCR to generate a new pool of mRNA molecules encoding the enriched sdAbs. The selection process is repeated to improve the affinity and specificity of the selected sdAbs.

Ribosome display selection cycle.

In Vitro Translation

In vitro translation involves transcribing the DNA sequences in the library into mRNA and then translating the mRNA into sdAbs using a cell-free system. The resulting sdAbs are associated with their mRNA progenitors, forming ribosome-mRNA-protein complexes.

Elution and Amplification

The immobilized complexes are eluted using high salt concentrations, chelating agents, or mobile ligands that disrupt binding interactions to recover the mRNA encoding the binding sdAbs. The mRNA is reverse transcribed to generate cDNA for further amplification and mutagenesis.

Technical Advantages and Optional Display Systems

Technical Advantages

  • Enhance the stability and solubility of sdAbs
  • Unlimited sequence diversity
  • Facile directed evolution
  • Streamlined Workflow

Optional Display Systems

  • Prokaryotic Ribosome Display System
  • Eukaryotic Ribosome Display System
  • Ribosome-Inactivation Display System (RIDS)
  • And More

Our Advantages

Time-saving services with high efficiency

Professional and experienced team

Cutting edge technology platform

Numerous service cases and customer praise

Through the integration of cutting-edge technologies, our company continues to drive advancements in antibody discovery, offering tailored solutions for various therapeutic challenges. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.

References

  1. Galán A, Comor L, Horvatić A, et al. Library-based display technologies: where do we stand?[J]. Molecular BioSystems, 2016, 12(8): 2342-2358.
  2. Kunamneni A, Ogaugwu C, Bradfute S, et al. Ribosome display technology: applications in disease diagnosis and control[J]. Antibodies, 2020, 9(3): 28.

For research use only, not for clinical use.